Please login to the form below

Not currently logged in
Email:
Password:

WE UK

This page shows the latest WE UK news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body. ... initial assessment, ”commented Jessamy Baird, director of patient access UK &Ireland at Sanofi.

Latest news

  • WE Communications wins BenevolentAI account WE Communications wins BenevolentAI account

    WE Communications UK has been appointed by BenevolentAI to bolster its integrated communications and marketing efforts. ... Specialising in health and technology brands, WE Communications aims to raise the artificial intelligence-focused group ’s

  • EC grants MSD’s Prevymis orphan product designation EC grants MSD’s Prevymis orphan product designation

    Louise Houson, UK managing director of MSD, said: “MSD is delighted that the EC has recognised the potential of letermovir for prophylaxis of CMV reactivation in certain patients in need of ... Houson continued: “This authorisation brings us a step

  • emotive partners with Rare Disease UK for public awareness campaign emotive partners with Rare Disease UK for public awareness campaign

    Jayne Spink, chair of Rare Disease UK, said: “We need to change this if we are to reduce feelings of isolation, and increase understanding of the common issues faced by patients ... Chris Edmonds, managing director at emotive, said: “We were

  • Dr Fiona Marshall heads up MSD's new UK research facility Dr Fiona Marshall heads up MSD's new UK research facility

    We are pleased to welcome her to MSD, where she will set an enormously high standard as the leader of our new London-based, UK discovery research centre.”. ... I relish the challenge of leading MRL”s new team of scientists in the UK as we embark upon

  • Transforming access in rare diseases Transforming access in rare diseases

    At Duchenne UK, we wanted to see if we could find a way to support prompt access to medicines, without compromising on the integrity of the evidence and working with the ... And we think we have found a way that works, not just in the UK but in other

More from news
Approximately 0 fully matching, plus 233 partially matching documents found.

Latest Intelligence

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    The key point is that this is all happening now; where will the UK be in 2020 when we leave the EU? ... On the face of it, we should therefore welcome the news that the UK and the EU have tentatively agreed to a Brexit transition period - which would

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    But we don’t need any more pilots; the concept has been proven.”. ... Budget silos. “Globally and in the UK, we are leading in this area because we are collaborating, being transparent about our intent, across different countries looking at pricing

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    And Brexit is adding to this uncertainty. At Bayer, we are committed to the UK and want to ensure that patients will have a secure access to medicines on day one ... If we can achieve this, we will help safeguard an undisturbed medicine supply to

  • Academic-industry collaboration in the era of big data Academic-industry collaboration in the era of big data

    Academic-industry collaboration in the era of big data. A window on the UK. ... For now, we know that the UK will roll out the new General Protection Data Regulation in 2018, as the rest of Europe will, so at least there will be a

  • Biologic or biosimilar: what are prescribers thinking? Biologic or biosimilar: what are prescribers thinking?

    Do I trust those companies to the same extent? I don’t know.” (UK). ... We are human, so we can be influenced by this.” (UK).

More from intelligence
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest appointments

  • Pfizer’s Alan Maine moves to Edelman Pfizer’s Alan Maine moves to Edelman

    Prior to his time with Pfizer, Maine was head of government affairs at Wyeth Pharmaceuticals - later acquired by Pfizer - and has held other roles withmanaging director for Edelman UK, said: “We ... are very excited about Alan joining Edelman as he

  • WE UK appoints Catherine Devaney as head of health WE UK appoints Catherine Devaney as head of health

    WE UK appoints Catherine Devaney as head of health. She joins the digital and comms agency from Red Door Unlimited. ... Public relations group WE UK has appointed Catherine Devaney to head up its health sector business to bolster the agency’s global

  • Executive Insight strengthens UK presence with new partner Executive Insight strengthens UK presence with new partner

    Executive Insight strengthens UK presence with new partner. David Ewbank joins the firm from McCann Health. ... Andrea Sobrio, managing partner, Executive Insight, said: “With his extensive background, David is well positioned to play an integral role

  • Peter Kelly named managing director of Accord Healthcare UK Peter Kelly named managing director of Accord Healthcare UK

    Peter Kelly named managing director of Accord Healthcare UK. He was previously commercial director at Actavis UK. ... We remain committed to R&D and bringing cost competitive new products to market at the earliest opportunity.

  • Sanofi appoints general manager UK Sanofi appoints general manager UK

    Fry said: “ I am honoured to be appointed as general manager for the UK. “ ... I am proud and motivated to lead our more than 1, 800 UK colleagues, who continuously demonstrate their commitment to serving the people whose lives we touch. “

More from appointments
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Gill Adair announced as Global Head of Talent Acquisition

    Ashfield Healthcare Communications employs 700 staff worldwide with more than 350 UK-based associates. ... Ashfield Healthcare Communications has always placed great emphasis on the importance of the individual, and now that we’ re bringing together

  • Portfolio Optimisation: Can you really compare Apples to Oranges?

    Do we really need to review our portfolio of existing or future offerings? ... Therapeutic, Diagnostic or Medical Device). Please contact the team at sales@blackswan-analysis.co.uk to learn more about how we can either run the process for your company or

  • Portcullis Public Affairs

    We help Government reach better decisions. Portcullis is in partnership with MAP BioPharma which helps clients navigate the detailed processes so as to achieve optimal market access in the UK, Ireland ... Together, we provide a unique combination of

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics